Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparison of mortality outcomes in individuals with MASLD and/or MAFLD
Qianwen Zhao, Yunlei Deng
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. e62-e64
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
Rui Song, Li Zhao, Yingzhi Zhang, et al.
Liver International (2024) Vol. 44, Iss. 4, pp. 1051-1060
Closed Access | Times Cited: 50
MAFLD: Exploring the Systemic Effects Beyond Liver.
Utkarsh Dayal, Ujjwal Soni, Sourav Bansal, et al.
Journal of Community Hospital Internal Medicine Perspectives (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Steatotic liver disease, MASLD and risk of chronic kidney disease
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, et al.
Diabetes & Metabolism (2023) Vol. 50, Iss. 1, pp. 101506-101506
Open Access | Times Cited: 35
Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
Yuxiao Jiang, Lili Wu, Xiaopeng Zhu, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice
Clémence M. Canivet, Jérôme Boursier, Rohit Loomba
Seminars in Liver Disease (2024) Vol. 44, Iss. 01, pp. 035-042
Closed Access | Times Cited: 9
Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence
Shadi Zerehpooshnesfchi, Amedeo Lonardo, Jian-Gao Fan, et al.
Metabolism and Target Organ Damage (2025) Vol. 5, Iss. 1
Open Access | Times Cited: 1
Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
Yasser Fouad, Hasmik Ghazinyan, Mohamed Alboraie, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 5, pp. e194-e197
Open Access | Times Cited: 8
Association of MAFLD and MASLD with all-cause and cause-specific dementia: a prospective cohort study
Xue Bao, Lina Kang, Songjiang Yin, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 8
The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations
Ziyan Feng, Fanrong Zhao, Ziyao Wang, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 7
Why MASLD Lags Behind MAFLD: A Critical Analysis of Diagnostic Criteria Evolution in Metabolic Dysfunction-Associated Liver Diseases
Mohamed Alboraie, Amna Subhan Butt, Alejandro Piscoya, et al.
Medical Science Monitor (2024) Vol. 30
Closed Access | Times Cited: 7
Hs-CRP and HOMA-IR: include them in the MASLD definition, or treat them as mediators between MASLD and atherosclerotic cardiovascular disease?
Heng Wan, Zihao Gui, Lan Liu, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 7
Comparison of NAFLD, MAFLD And MASLD Prevalence And Clinical Characteristics in Asia Adults
Xinjuan Huang, Ruoling Yu, Xinyun Tan, et al.
Journal of Clinical and Experimental Hepatology (2024) Vol. 15, Iss. 1, pp. 102420-102420
Closed Access | Times Cited: 7
Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification
Min Kyu Kang, Jeong Eun Song, Rohit Loomba, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Leisure-Time Physical Activity in Subjects with Metabolic-Dysfunction-Associated Steatotic Liver Disease: An All-Cause Mortality Study
Ritanna Curci, Caterina Bonfiglio, Isabella Franco, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 13, pp. 3772-3772
Open Access | Times Cited: 5
Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10‐year follow‐up period
Kazuma Mori, Marenao Tanaka, Tatsuya Sato, et al.
Hepatology Research (2024)
Open Access | Times Cited: 5
Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study
So Hyun Cho, Seohyun Kim, Rosa Oh, et al.
Hepatology International (2024) Vol. 18, Iss. 4, pp. 1168-1177
Closed Access | Times Cited: 4
The MAFLD and MASLD conundrum: Is it reinvention of the wheel?
Mariana M. Ramírez-Mejía, Mohammed Eslam, Nahúm Méndez‐Sánchez
Journal of Hepatology (2024) Vol. 81, Iss. 1, pp. e22-e23
Closed Access | Times Cited: 3
Impact of steatotic liver disease subtypes, sarcopenia, and fibrosis on all-cause and cause-specific mortality: a 15.7-year cohort study
Yebei Liang, Xiaoqi Ye, Min Pan, et al.
BMC Gastroenterology (2025) Vol. 25, Iss. 1
Open Access
Prognostic and predictive effects of new steatotic liver disease nomenclatures: a large population‐based study
Huixian Zeng, Letian Fang, Zhiyu Yang, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access
Insights into Clinical Trials for Drugs Targeting MASLD: Progress, Challenges, and Future Directions
Yu Wu, Pu Dong, Q H Wu, et al.
Clinical Pharmacology & Therapeutics (2025)
Closed Access
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, et al.
Exploration of Medicine (2025)
Open Access
Metabolic dysfunction associated steatotic liver disease is associated with atrial fibrillation recurrence following cryoballoon ablation
Yu Wang, Zheng Chen, Bo Wei, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Sex-specific effects of aged polystyrene microplastics on hepatic AMPK pathway activation and lipid droplet accumulation in MAFLD mice
Qing Wang, Xiaona Yang, Chuan Chen, et al.
Ecotoxicology and Environmental Safety (2025) Vol. 292, pp. 117963-117963
Open Access
Sleep Duration, Midpoint, Variability, Irregularity and Metabolic Dysfunction-Associated Steatotic Liver Disease
Qingcui Wu, Fuhai Song, Huijie Huang, et al.
Behavioral Sleep Medicine (2025), pp. 1-14
Closed Access
Comparative association of MAFLD/MASLD and Subtypes with Cardiovascular Diseases Outcomes
Huizhen Jin, Zhuoshuai Liang, Xinmeng Hu, et al.
Nutrition Metabolism and Cardiovascular Diseases (2025), pp. 104024-104024
Closed Access
Page 1 - Next Page

Scroll to top